Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 05, 2016 6:25 PM ET


Company Overview of FORMA Therapeutics, Inc.

Company Overview

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically-driven diseases. The company’s drug discovery engine deploys screening and structure-based approaches across various families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. It has a strategic partnership with Celgene Corporation. FORMA Therapeutics, Inc. was formerly known as Forma Pharmaceuticals, Inc. and changed its name to FORMA Therapeutics, Inc. in February 2008. The company was incorporated in 2007 and is based in Watertown, Massachusetts and has additional chemistry operations in Branford, Connecticut. FORMA Therapeutics, Inc. operat...

500 Arsenal Street

Suite 100

Watertown, MA 02472

United States

Founded in 2007





Key Executives for FORMA Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Director
Chief Financial Officer
Head of Biomolecular Screening and Executive Director
Chief Business Officer
Compensation as of Fiscal Year 2015.

FORMA Therapeutics, Inc. Key Developments

FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies

FORMA Therapeutics announced the initiation of a Phase 1 study of FT-1101, with the first dose administration in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. FT-1101 is an oral, structurally distinct and potent pan-inhibitor of the BET (Bromodomain and Extra-Terminal) epigenetic protein family. Small molecule inhibition of BET results in down-regulation of the critical oncogene MYC, a master regulator of diverse cell functions critical for cell growth and survival in many cancers. At tolerated doses in human tumor xenograft mousemodels, FT-1101 has demonstrated significant anti-tumor activity including tumor regressions. FT-1101 is part of FORMA’s second global strategic collaboration with Celgene Corporation announced in April 2014. Celgene has obtained an exclusive EU license for FT-1101 in exchange for an undisclosed payment to FORMA. Under the terms of the collaboration agreement, FORMA will advance the FT-1101 program through Phase 1, and Celgene will be responsible to fund and execute further global clinical development. The Phase 1 multicenter, open-label, dose escalation clinical trial is designed to assess the safety and tolerability of FT-1101 capsules as a single agent. FT-1101 will be administered orally on a once weekly dosing schedule in a 28-day cycle. The study will enroll patients with relapsed refractory AML and high risk myelodysplastic syndrome. Key objectives in the study include determination of a maximum tolerated dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of FT-1101.

Forma Therapeutics and Cancer Research Technology Form A Third Virtual Company to Advance Deubiquitination Assets

FORMA Therapeutics and Cancer Research Technology Ltd. announced the formation of a third new virtual Asset Discovery and Development Company with novel chemical matter targeting an undisclosed deubiquitinating enzyme (DUB). ADDCos are virtual companies that rapidly advance drug discovery innovations in a compelling scientific area through the collaboration of academic thought leaders, FORMA drug discovery scientists and a world class development network. Under the agreement, FORMA is pairing its ultra-efficient drug discovery and early development capabilities with expertise from CRT’s Discovery Laboratories (CRT-DL) and the exclusive world-class academic network of Cancer Research UK scientists.

FORMA Therapeutics, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 09:30 AM

FORMA Therapeutics, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 09:30 AM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Steven Tregay, Co-Founder, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Boston Biomedical, Inc. United States
Vedanta Biosciences, Inc. United States
IgDraSol Inc. United States
Promega Biosciences, LLC United States
Gencia Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact FORMA Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at